Grant

A Phase I/II, Randomized, Double-blind, Sham Control Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Ascending Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gen

Sponsored by UniQure

Active

$1.1M Funding

2 People

External

Related Topics

gene therapy, neurodegenerative diseases, clinical trial, genetic disorders, drug safety

People

Shamam Hashim
(CD)
Surgery﹒Clinical Research Coordinator III
Kirsten Anderson
(CD)
Az Health Sciences Division﹒Research Compliance Administrator IV